Novartis’ crizanlizumab wins speedy FDA review, putting it closer to blockbuster sickle cell launch
admin 16th July 2019 Uncategorised 0Novartis’ plan to launch over 10 potential blockbuster drugs or new indications by 2021 is quickly unfolding. The FDA has accepted a biologics application for the pharma giant’s sickle cell disease candidate crizanlizumab.
More: Novartis’ crizanlizumab wins speedy FDA review, putting it closer to blockbuster sickle cell launch
Source: fierce